Interstitial lung disease in systemic sclerosis: current and future treatment.

about

P2860

Q41105228-6BC0D706-68AF-4C21-97A7-F754DEB995EC Q47800521-4AA72C30-DBAC-4CE3-A678-6DEDEA306FF4 Q49705100-B05FAC0B-1373-4845-B35C-352C13D2ECFC Q58585474-FCBF9D58-FBE3-4570-A2E6-0F5875AB7118 Q58779775-A22DF3C5-76D9-413A-971C-C6DF5929BB52

P2860

Interstitial lung disease in systemic sclerosis: current and future treatment.

Item

http://www.wikidata.org/entity/Q38773637

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Interstitial lung disease in systemic sclerosis: current and future treatment.

@en

type

Item

label

Interstitial lung disease in systemic sclerosis: current and future treatment.

@en

prefLabel

Interstitial lung disease in systemic sclerosis: current and future treatment.

@en

P1476

Interstitial lung disease in systemic sclerosis: current and future treatment.

@en

P2093

Francesco Carubbi

http://www.w3.org/2001/XMLSchema#string

Francesco Ciccia

http://www.w3.org/2001/XMLSchema#string

Giovanni Triolo

http://www.w3.org/2001/XMLSchema#string

Giuliana Guggino

http://www.w3.org/2001/XMLSchema#string

Onorina Berardicurti

http://www.w3.org/2001/XMLSchema#string

Paola Cipriani

http://www.w3.org/2001/XMLSchema#string

Piero Ruscitti

http://www.w3.org/2001/XMLSchema#string

Roberto Giacomelli

http://www.w3.org/2001/XMLSchema#string

Salvatore Di Bartolomeo

http://www.w3.org/2001/XMLSchema#string

P2860

Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial

American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Soci

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expression

Increase in activated T cells and reduction in suppressor inducer T cells in systemic sclerosis.

B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial.

The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.

Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression.

Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study.

Cyclophosphamide versus placebo in scleroderma lung disease.

P2888

s00296-016-3636-7

P304

853-863

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00296-016-3636-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Paola Di Benedetto

Vasiliki Liakouli

P577

2017-01-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1022923236

http://www.w3.org/2001/XMLSchema#string

P698

28063071

http://www.w3.org/2001/XMLSchema#string

Interstitial lung disease in systemic sclerosis: current and future treatment.

about

P2860

P2860

Interstitial lung disease in systemic sclerosis: current and future treatment.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698